FDA Taking Steps To Simplify Combo Product Consultations
This article was originally published in The Tan Sheet
Executive Summary
The agency releases an internal assessment of how it handles inter-center consultations for combination products. As expected, there are some serious challenges to collaboration between the centers, but FDA says it is taking tangible steps to make it better.
You may also be interested in...
Senate Bill Aimed At Streamlining Combo Product Regulation
A Senate bill would streamline device/drug combination registrations at FDA by letting the agency rely on prior PMAs and approved drug findings to help support new product approvals, among other reforms. It was introduced by Sen. Johnny Isakson, R-Ga., and co-sponsored by Sens. Robert Casey, D-Pa., and Pat Roberts, R-Kansas.
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Top FDA officials, including CDRH Director Jeffrey Shuren and FDA Deputy Commissioner Robert Califf, are sending strong signals that the designation and review processes for combination products are due for a significant reassessment. That should be a priority topic of upcoming user fee negotiations with industry, they say.
Human Factors Questions Drive Rise In FDA Inter-Center Consults
Formal consultations between FDA's product centers are becoming more frequent, and they are often triggered by questions about human factors issues, says Office of Combination Products Director Thinh Nguyen.